Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

NIVOLUMAB for Malignant melanoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 10,599 adverse event reports in the FDA FAERS database where NIVOLUMAB was used for Malignant melanoma.

Most Reported Side Effects for NIVOLUMAB

Side Effect Reports % Deaths Hosp.
Death 11,216 12.8% 11,211 780
Malignant neoplasm progression 9,363 10.7% 5,146 4,330
Off label use 5,208 5.9% 1,240 1,725
Diarrhoea 4,692 5.4% 623 2,506
Fatigue 3,709 4.2% 409 1,425
Pyrexia 3,454 3.9% 532 2,501
Intentional product use issue 3,297 3.8% 1,461 827
Rash 2,816 3.2% 297 1,131
Nausea 2,805 3.2% 378 1,495
Decreased appetite 2,619 3.0% 452 1,429
Dyspnoea 2,527 2.9% 596 1,575
Pneumonia 2,281 2.6% 792 1,676
Colitis 2,123 2.4% 333 1,306
Pneumonitis 2,076 2.4% 564 1,130
Hypothyroidism 1,939 2.2% 267 946

Other Indications for NIVOLUMAB

Product used for unknown indication (12,733) Non-small cell lung cancer (9,987) Renal cell carcinoma (6,514) Metastatic malignant melanoma (4,628) Lung neoplasm malignant (4,197) Metastatic renal cell carcinoma (3,857) Gastric cancer (3,856) Non-small cell lung cancer recurrent (2,703) Renal cancer (1,756) Oesophageal carcinoma (1,555)

Other Drugs Used for Malignant melanoma

IPILIMUMAB (8,903) DABRAFENIB (5,277) TRAMETINIB DIMETHYL SULFOXIDE (3,841) PEMBROLIZUMAB (3,261) BINIMETINIB (2,613) ENCORAFENIB (2,591) VEMURAFENIB (2,548) TRAMETINIB (1,448) COBIMETINIB (1,324) TALIMOGENE LAHERPAREPVEC (562)

Related Pages

NIVOLUMAB Full Profile All Malignant melanoma Drugs NIVOLUMAB Demographics NIVOLUMAB Timeline